• Prescribing Information
  • For Healthcare Professionals

Login
  • My Account
  • Logout
  • Home
  • Neurofibromatosis type 1
    • Understanding NF1
    • Pathogenesis of NF1
    • Clinical Presentation of NF1
    • Diagnosis of NF1
  • About Koselugo®
    • What is Koselugo®
    • SPRINT Study
    • Efficacy
  • Safety Profile
  • Dosage and Administration
  • Resources
    • Dosing Card
    • Video Resources
    • Glossary
    • Reporting Adverse Event
  • Contact Us

Welcome

Please select one of the following options

The content on this website is intended for healthcare professionals only.

The website contains both promotional and non-promotional content.

I AM A PATIENT/MEMBER OF THE PUBLIC
  • Contact Us

Not An Actual Patient

To request medical information about Koselugo®, visit http://contactazmedical.astrazeneca.com. In order to monitor the safety of AstraZeneca products,
we encourage clinicians to report suspected adverse events to AstraZeneca at http://contactazmedical.astrazeneca.com.

Contact us:

Address: AstraZeneca Sdn Bhd (69730-X)
The Bousteador, Level 12, No. 10, Jalan PJU 7/6, Mutiara Damansara, 47800, Petaling Jaya, Selangor, Malaysia

T:+603 7624 3888

F:+603 7624 3999

Email:For enquiries, please email us at koselugomy@astrazeneca.com. Kindly note this is for HCPs only. If you are a patient requiring assistance, please reach out to your consulting physician.

  • Privacy Policy
  • Terms of Use
  • Cookie Policy
  • Sitemap

MY-14129_JAN2025 | © ASTRAZENECA 2025 ALL RIGHTS RESERVED